An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

A new poll from The Associated Press-NORC Center for Public Affairs Research looks at what U.S. adults think about ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...